BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced an upcoming poster at the upcoming 2024 MDA Clinical & Scientific Conference taking place March 3-6 in Orlando.

Frontier Medicines Corporation announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.

Pyxis Oncology, Inc. today announced that it has agreed to sell 8,849,371 shares of its common stock at a price of $4.78 per share.

Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.

ReWalk Robotics Ltd., a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced its financial results for the three months and full year ended December 31, 2023.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after market close on Tuesday, March 5 , 2024.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.

Aria CV, Inc today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.

Glucotrack, Inc. announced the selection of Cirtec Medical Corp, the leading medical device solutions provider of implantable therapies, as manufacturer for the implantable Continuous Blood Glucose Monitor.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.